Literature DB >> 1416902

Bioavailability of rifampin in experimental murine tuberculosis.

J Dickinson, A Guy, D A Mitchison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1416902      PMCID： PMC192441          DOI： 10.1128/AAC.36.9.2066

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  3 in total

1.  Drug combinations and the bioavailability of rifampicin.

Authors:  W Fox
Journal:  Tubercle       Date:  1990-12

2.  Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.

Authors:  H F Lecoeur; C Truffot-Pernot; J H Grosset
Journal:  Am Rev Respir Dis       Date:  1989-11

3.  Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.

Authors:  J Grosset; C Truffot-Pernot; C Lacroix; B Ji
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191
  3 in total
  10 in total

1.  Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.

Authors:  Eric Nuermberger; Ian Rosenthal; Sandeep Tyagi; Kathy N Williams; Deepak Almeida; Charles A Peloquin; William R Bishai; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of Mycobacterium avium Infection.

Authors:  Jean-Philippe Lanoix; Cédric Joseph; François Peltier; Sandrine Castelain; Claire Andréjak
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

3.  A physiologically based pharmacokinetic model of rifampin in mice.

Authors:  Michael A Lyons; Brad Reisfeld; Raymond S H Yang; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

4.  Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.

Authors:  Rosemary V Swanson; Nicole C Ammerman; Bongani Ngcobo; John Adamson; Chivonne Moodley; Afton Dorasamy; Sashen Moodley; Zinhle Mgaga; Linda A Bester; Sanil D Singh; Deepak V Almeida; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

5.  Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Authors:  Sandeep Tyagi; E Nuermberger; T Yoshimatsu; K Williams; I Rosenthal; N Lounis; W Bishai; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

6.  Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.

Authors:  K N Williams; C K Stover; T Zhu; R Tasneen; S Tyagi; J H Grosset; E Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

7.  Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.

Authors:  Deepak Almeida; Eric Nuermberger; Rokeya Tasneen; Ian Rosenthal; Sandeep Tyagi; Kathy Williams; Charles Peloquin; Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

8.  Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.

Authors:  J Dhillon; J M Dickinson; K Sole; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.

Authors:  Rokeya Tasneen; Sandeep Tyagi; Kathy Williams; Jacques Grosset; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

10.  Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide.

Authors:  Jacques Grosset; Deepak Almeida; Paul J Converse; Sandeep Tyagi; Si-Yang Li; Nicole C Ammerman; Alexander S Pym; Kristina Wallengren; Richard Hafner; Umesh Lalloo; Susan Swindells; William R Bishai
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.